It is well known that the subjective symptoms and objective indicators of prostatic hyperplasia tend to worsen progressively as the patient ages and the course of the disease increases. The following factors have been found to be closely related to: 1. age: research data suggest that the risk of acute urinary retention and the need for surgical procedures in patients with BPH increases with age; the likelihood of clinical progression is greater in patients with BPH ≥ 62 years of age; 2. serum PSA: many studies now suggest that serum PSA can predict the increase in prostate volume, maximum The MTOPS study showed that patients with BPH with a serum PSA greater than 1,6 ng/ml were at greater risk of clinical progression; 3. Prostate volume: Prostate volume predicts the risk of acute urinary retention and the likelihood of undergoing surgical procedures in patients with BPH. The most recent MTOPS study showed that patients with BPH with a prostate volume ≥ 31 ml were at a significantly increased risk of clinical progression; 4. 5. Residual urine volume: The recent MTOPS study showed that patients with BPH with residual urine volume ≥ 39 ml were at significantly increased risk of clinical progressiveness. 6. I-PSS score: Data indicate that patients with I-PSS score >7 have 4 times higher risk of acute urinary retention than those with I-PSS score <7. 7. Chronic inflammation of the prostate: In a randomized controlled trial study, it was found that the patients who experienced acute urinary retention in the trial were those whose biopsy suggested chronic inflammation of the prostate, and none of the patients without chronic prostatitis experienced acute The study found that the patients who had acute urinary retention were those whose biopsies suggested chronic inflammation of the prostate. Therefore, chronic inflammation of the prostate may be one of the factors predicting the clinical progressiveness of BPH; 8, metabolic syndrome: metabolic syndrome is a pathological state of abnormal aggregation of multiple metabolic components, a complex group of metabolic disorders syndrome. A foreign study suggests that: the more patients who meet the diagnostic conditions of metabolic syndrome, the more risk they have of more than one risk factor for BPH progression, and the proportion of prostate volume greater than or equal to 31 ml, or residual urine volume greater than or equal to 39 ml increases significantly. This suggests that metabolic syndrome may be one of the factors predicting clinical progressiveness of BPH; 9. Intravesical prostatic prominence (IPP): recent studies have shown that transabdominal ultrasound measurement of IPP through the midline sagittal plane can predict the likelihood of failed extubation in patients with acute urinary retention. It has also been shown that prostate volume, serum PSA values, and residual urine volume increase more significantly in BPH patients with IPP greater than 10 mm, and that the incidence of acute urinary retention is higher, so patients with IPP greater than 10 mm are likely to benefit from early surgical intervention; a study from Singapore even showed that IPP was superior to PSA and prostate volume as a predictor of bladder outlet obstruction. Thus IPP may become a new risk factor for clinical progression of BPH. In addition, long-term hypertensive prostatic migratory zone volume and migratory zone index may also be associated with clinical progression of BPH. It has also been suggested that non-response to partial alpha blockers may be an important risk factor predicting BPH disease progression and may help to screen out patients at high risk for clinically progressive BPH.